UNCYUnicycive Therapeutics, Inc.

Nasdaq unicycive.com


$ 0.38 $ 0.02 (6.25 %)    

Monday, 09-Sep-2024 15:43:00 EDT
QQQ $ 453.78 $ 1.25 (0.28 %)
DIA $ 408.87 $ 1.54 (0.38 %)
SPY $ 545.86 $ 1.19 (0.22 %)
TLT $ 99.96 $ 0.58 (0.58 %)
GLD $ 231.53 $ 0.27 (0.12 %)
$ 0.3541
$ 0.36
$ 0.38 x 300
$ 0.38 x 600
$ 0.36 - $ 0.38
$ 0.20 - $ 1.82
508,114
na
33.3M
$ -2.22
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2024 06-30-2024 10-Q
2 05-13-2024 03-31-2024 10-Q
3 03-28-2024 12-31-2023 10-K
4 11-14-2023 09-30-2023 10-Q
5 08-14-2023 06-30-2023 10-Q
6 05-16-2023 03-31-2023 10-Q
7 03-31-2023 12-31-2022 10-K
8 11-14-2022 09-30-2022 10-Q
9 08-15-2022 06-30-2022 10-Q
10 05-12-2022 03-31-2022 10-Q
11 03-31-2022 12-31-2021 10-K
12 11-11-2021 09-30-2021 10-Q
13 08-16-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 benchmark-reiterates-speculative-buy-on-unicycive-therapeutics-maintains-3-price-target

Benchmark analyst Bruce Jackson reiterates Unicycive Therapeutics (NASDAQ:UNCY) with a Speculative Buy and maintains $3 pric...

 hc-wainwright--co-reiterates-buy-on-unicycive-therapeutics-maintains-25-price-target

HC Wainwright & Co. analyst Ed Arce reiterates Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and maintains $2.5 price ...

 hc-wainwright--co-maintains-buy-on-unicycive-therapeutics-lowers-price-target-to-25

HC Wainwright & Co. analyst Ed Arce maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and lowers the price targe...

 unicycive-secures-patent-for-kidney-disease-treatment-uni-494-valid-until-2040

Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidne...

 hc-wainwright--co-reiterates-buy-on-unicycive-therapeutics-maintains-45-price-target

HC Wainwright & Co. analyst Ed Arce reiterates Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and maintains $4.5 price ...

 unicycive-therapeutics-inc-files-for-resale-of-up-to-50m-shares-by-the-selling-stockholders

- SEC Filing

 unicycive-therapeutics-joins-russell-microcap-index

Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidne...

 hc-wainwright--co-reiterates-buy-on-unicycive-therapeutics-maintains-45-price-target

HC Wainwright & Co. analyst Ed Arce reiterates Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and maintains $4.5 price ...

 benchmark-reiterates-speculative-buy-on-unicycive-therapeutics-maintains-3-price-target

Benchmark analyst Bruce Jackson reiterates Unicycive Therapeutics (NASDAQ:UNCY) with a Speculative Buy and maintains $3 pric...

 benchmark-reiterates-speculative-buy-on-unicycive-therapeutics-maintains-3-price-target

Benchmark analyst Bruce Jackson reiterates Unicycive Therapeutics (NASDAQ:UNCY) with a Speculative Buy and maintains $3 pric...

 hc-wainwright--co-reiterates-buy-on-unicycive-therapeutics-maintains-45-price-target

HC Wainwright & Co. analyst Ed Arce reiterates Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and maintains $4.5 price ...

 unicycive-showcases-data-on-kidney-disease-therapies-at-european-renal-congress

Unicycive Therapeutics Delivers Multiple Presentations on Oxylanthanum Carbonate (OLC) and UNI-494 at the European Renal Associ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION